Stay updated with breaking news from Sergio Traversa. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Company Well-Positioned for a Pivotal 2024 with Multiple Key Clinical Development Milestones Anticipated Relmada's Strong Balance Sheet to Support the Company Through All of 2024's Expected Critical...
Operator: Good afternoon, ladies and gentlemen. And welcome to Relmada Therapeutics, Inc. Third Quarter 2023 Earnings Conference Call. At this time, all lines are in listen-only mode.
Progress in Clinical Development and Financial Highlights
/PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today...
CORAL GABLES, Fla., Aug. 8, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a corporate update